2019-07-31

[#DIV28M] Postdoctoral Opportunity in Behavioral Pharmacology of Substance Use Disorder

The Collins Laboratory in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio (UTHSCSA) is seeking a highly motivated and creative Postdoctoral Fellow to conduct innovative NIDA- and VA-funded research on the behavioral pharmacology of Substance Use Disorders. Current research in our laboratory is focused on: 1) investigating behavioral and neuropharmacological factors that underlie the development of compulsive drug taking; 2) understanding how interactions among drugs at the center of the current overdose epidemic (e.g., methamphetamine and fentanyl) impact their abuse-related and toxic effects; and 3) developing novel polypharmacy approaches to targeting dopamine and serotonin systems for the treatment of substance use disorder. Through this fellowship, the selected candidate will gain expertise in a variety of behavioral techniques, including rodent self-administration and implantable telemetry, as well as the application of quantitative analyses to the study of drugs, drug-drug interactions, and behavior. The selected candidate will be encouraged to develop an independent line of research. Additional structured opportunities for scientific and career development are provided by a NIDA-funded T32 training grant.

Eligibility: Candidates should have a recent doctoral degree in Pharmacology, Neuroscience, Experimental Psychology, or a related discipline, and a strong interest in conducting drug abuse research. Prior experience with rodent or non-human primate behavior is preferred, but not essential.

To apply: Send a CV, a brief statement of research/training goals, and the names and contact information of three references to Gregory T. Collins, Ph.D. (collinsg@uthscsa.edu). Review of applications will begin immediately and continue until the position is filled.

UTHSCSA is an Equal Opportunity/Affirmative Action Employer.

__________________ Div28m@lists.apa.org ___________________
restricted to APA members subscribers corner: http://lists.apa.org

2019-07-27

[#DIV28SUPER] Director Search School of Psychology at Southern Miss

Colleagues,

I am excited to announce we are searching for a Director (Department Chair) for our School of Psychology. Please see info below. I’m happy to answer any questions about Southern Miss etc. Mike

The School of Psychology at The University of Southern Mississippi is seeking to fill the School Director (Department Chair) position beginning July, 2020. The School of Psychology has approximately 600 undergraduate majors and 125 graduate students across three APA-accredited doctoral programs (Counseling, Clinical, & School), a Brain and Behavior doctoral program and a Master’s program in Counseling Psychology.  Applicants for the School Director position should meet expectations for tenure and promotion to Full Professor at or within two years of hiring, possess research and external funding experience, and demonstrate strong leadership, communication and collaboration skills as well as administrative experience. Inquiries to the School Director position should be directed to Dr. Sandra Nichols (Sandra.nichols@usm.edu). For deadlines and more information, please visit jobs.usm.edu. Application materials can be uploaded to the HR site found here: https://jobs.usm.edu. The School is committed to increasing diversity; we encourage applications from those who identify as diverse in terms of gender, race, ethnicity, and/or sexual orientation AA/EEO/ADAI.

 

 

Michael B. Madson, Ph.D.

Professor of Psychology

The University of Southern Mississippi

118 College Dr #5025

Hattiesburg, MS 39406

601-266-4546

Michael.madson@usm.edu

USM BAR Lab

Facebook Page

Twitter: @UsmBar

 

Click on this link to unsubscribe from the DIV50DISCUSS list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list.

2019-07-24

[#DIV28SUPER] UNIVERSITY OF VERMONT NIH POSTDOCTORAL RESEARCH FELLOWSHIP OPPORTUNITY



UNIVERSITY OF VERMONT, CENTER ON BEHAVIOR AND HEALTH

POSTDOCTORAL RESEARCH FELLOWSHIP

 

The Vermont Center on Behavior and Health in the UVM College of Medicine announces an NIH postdoctoral research fellowship opportunity with Dr. Stacey Sigmon in our internationally recognized center of excellence for drug abuse research. The fellow will help to lead ongoing randomized clinical trials evaluating low-barrier, technology-assisted buprenorphine treatment for individuals with opioid use disorder (OUD), as well as develop new research opportunities aimed at expanding OUD treatment access in rural, underserved areas.  Dr. Sigmon, VCBH colleagues and our 29-year training program have an exceptional track record of helping fellows to establish successful careers as independent investigators.

 

Eligibility: Applicants must have completed their training in psychology or a related discipline and be U.S. citizens or permanent residents. Trainees are selected on the basis of scholastic record and commitment to a career in drug abuse research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise.

 

Appointment: 2-3 yrs.

 

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

 

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Stacey Sigmon c/o Ms. Marissa Palmer (marissa.palmer@uvm.edu).

 

About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within UVM and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.

 

For more information: Contact Ms. Marissa Palmer, marissa.palmer@uvm.edu or see our website.

 

Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.


--

Stephen T. Higgins, Ph.D.
Director, Vermont Center for Behavior and Health
Professor and Virginia H. Donaldson Chair in Translational Science, Departments of Psychiatry and Psychological Science
University of Vermont
1 South Prospect Street
Burlington, VT  05401-1419

2019-07-23

[#DIV28SUPER] The 2019 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention, Friday, October 18, 2019, 8:30 AM – 5:30 PM, Marriott Marquis, Grand Lakes Ballroom E & F, Chicago, IL, a satellite event of the annual meeting of the Society for Neuroscience

The 2019 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention will be held on Friday, October 18, 2019, 8:30 AM – 5:30 PM, Marriott Marquis, Grand Lakes Ballroom E & F, Chicago, IL, a satellite event of the annual meeting of the Society for Neuroscience [SfN].

 

The annual NIDA-NIAAA Mini-Convention provides a forum for presentations and discussions of current topics in neuroscience and addiction research. Additionally, the Mini-Convention showcases research by premier early stage and junior investigators and is highlighted by a keynote address from the Jacob P. Waletzky Memorial Award Recipient. This year's scientific sessions are: 1) Sensing New Opportunities for Addiction Neuroscience; 2) Novel Technologies and Innovative Approaches for Translational Research Targeting Alcohol and Substance Use Disorders; and 3) Rewriting Genes by CRISPR for Substance Dependence and Psychiatric Disorder Research. Event website coming soon. For additional information, please contact Roger Sorensen, NIDA [ rsorense@mail.nih.gov ] orJohn Matochik, NIAAA [ jmatochi@mail.nih.gov ].

 

 

NIDA and NIAAA are now soliciting applications for the Early Career Investigator Showcase [ECIS] to be held from 11:30 AM 1:00 PM during the 2019 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention.

 

The ECIS symposium provides a forum for scientific presentations by premier young and junior investigators working in the fields ofalcohol and substance abuse and addiction research. Applications can be submitted by intramural and extramural investigators. Up to 6 individuals will be chosen for the quality of their research, its impact in the field, and its relevance to the mission of NIDA or NIAAA. Applications consist of a brief description of the contribution of your research towards any of the Mini-Convention scientific sessions, yourCurriculum Vitae/Resume and list of publications, and are due by Friday, August 16, 2019 5:00 PM (EDT).  Individuals [extramural applicants only] selected to participate in the ECIS symposium will be given an award for travel expenses. For additional information, please contact Roger Sorensen, NIDA [ rsorense@mail.nih.gov ] or John Matochik, NIAAA [ jmatochi@mail.nih.gov ].

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2019-07-22

[#DIV28SUPER] NIDA Neuroscience Update, July 22, 2019

Table of Contents:

 

I.                    Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) RFA-DA-20-023

 

II.                  Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (Clinical Trial Optional)  PAR-19-039 and PAR-19-040

 

III.                Funding Opportunity: Methods to Improve Reproducibility of iPSC Derivation, Growth, and Differentiation RFA-GM-19-001

 

IV.                Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)    
PAR-19-310

 

V.                  Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research NOT-DA-19-041

 

VI.                Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-006

 

VII.              Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-007

 

 

I.                    Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) RFA-DA-20-023

Application Deadline: November 12, 2019

 

Description:

This Funding Opportunity Announcement supports projects aimed at the elucidation of microglia-neuronal pathophysiological mechanisms of HAND in the presence and absence of substances of abuse, using cerebral organoids and microglia derived from human iPSCs. It is expected that the latest 3D technology will be used to create the cerebral organoids. Investigators are encouraged to exploit state of-art technologies including Omics assays, genomic editing tools such as CRISPR, and single cell analysis and imaging approaches to address outstanding questions regarding molecular regulation of persistent HIV (e.g. latency or reservoirs) in the context of chronic substance use or substance use disorders (SUD).  Applications focused solely on alcohol exposure will be considered non-responsive to this FOA. 

II.                  Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (Clinical Trial Optional)  PAR-19-039 and PAR-19-040

Application deadline: September 10, 2019.

 

Description:

NIDA is announcing a high priority interest in receiving grant applications for the discovery and development of treatments to prevent and treat opioid-induced respiratory depression and overdose. Applications may focus on the development of new chemical entities, biologics, assay development, animal model development, new formulations, or combinations of medications that hold promise for the treatment of opioid overdose. A wide variety of treatment strategies will be considered including, but are not limited to, longer acting opioid-receptor antagonists, opioid sequestration agents and/or respiratory stimulants.

 

Please contact Kris Bough (boughk@mail.nih.gov) with questions.

 

III.                Funding Opportunity: Methods to Improve Reproducibility of iPSC Derivation, Growth, and Differentiation RFA-GM-19-001

Application Due date:

January 6, 2020, by 5:00 PM local time of applicant organization.

 

We want to let you know about a funding opportunity that may be of interest to you or others in your network. We are seeking Small Business Innovation Research (SBIR) applications to develop methods that improve the reproducibility of human induced pluripotent stem cell (iPSC) derivation, growth, and differentiation (RFA-GM-19-001). As you probably know, realizing the full potential of human iPSCs for both research and clinical practice has been limited by the significant variability in reprogramming efficiency, differentiation potential, and cell growth and stability. Overall, 11 NIH Institutes and centers intend to commit funds, with an estimated 25 awards. We hope this broad reach will help us develop novel, reliable, and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical uses. Applications will be accepted from December 6, 2019 through January 6, 2020.

 

 

IV. Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)    
PAR-19-310

Application Deadline: September 16, 2019

Description:

This Funding Opportunity will use a NIH Small Research Grant (R03) award mechanism designed to support innovation in development or use of new paradigms or theories to study affective, cognitive and behavioral processes contributing to substance use disorders (SUD). Proposals focused on new hypotheses, models, and/or methods, in both preclinical and clinical SUD research, are solicited. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time.   B/START-supported projects are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.

 

V. Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research NOT-DA-19-041

 

Expiration Date: January 8, 2022

Standard Application Dates Apply.

 

Description: The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) to encourage grant applications that will use ‘big data’ analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance use and addiction by developing more powerful analytical methods and visualization tools that can help capture the richness of different data types and across scales of analysis; including molecular, clinical, and electronic health records. Applications should develop and/or utilize computational approaches for analyzing large, complex datasets acquired from drug addiction research.

 

VI. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-006

Application Deadline: November 14, 2019

 

Description:

 

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology. 

 

VII. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-007

Application Deadline: November 14, 2019

 

Description: The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

 

VIII.            Leveraging Big Data Science to Elucidate the HIV Activity and Interaction with Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-008

Application Deadline: November 14, 2019

 

Description:

 

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.

 

IX.                Leveraging Big Data Science to Elucidate the HIV Activity and Interaction with Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-009

Application Deadline: November 14, 2019

 

Description:

 

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

http://list.nih.gov/cgi-bin/wa?SUBED1=nida_neuro_science-l&A=1&X=6F4BAE4CF706755A29&Y=nidaneurosc%40mail.nih.gov&A=0

2019-07-17

[DIV28ANNOUNCE] Division 28 July 2019 newsletter

Good afternoon APA Division 28,

 

Attached is the July issue of the division newsletter. I’m also attaching the PDF of Division 28 programming for the upcoming convention. Please enjoy!

 

Regards,

Erin McClure 

 

 

-------------
Erin A. McClure, Ph.D.
Assistant Professor
Addiction Sciences Division
Medical University of South Carolina
67 President St., MSC 861
Charleston, SC 29425
Phone: 843-792-7192

 

Like us on Facebook!  

 

2019-07-15

[#DIV28SUPER] 2019 Annual Vermont Center on Behavior & Health National Conference


PLEASE FORWARD BELOW AND ATTACHED:


7th Vermont Center on Behavior and Health Annual Conference
COMPLEMENTARY CONTRIBUTIONS OF TOBACCO CONTROL & REGULATORY SCIENCE RESEARCH TO PROTECTING THE PUBLIC HEALTH
October 10-11, 2019
Burlington Hilton Hotel, Burlington, Vermont

The 7th Annual VCBH Conference will focus on the intersection between tobacco regulatory science and tobacco control, two of the major fields in tobacco research. We will bring together renowned researchers in both fields to see how each may compliment one another to decrease tobacco use nationwide.

 

This year's keynote speaker is Dorothy Hatsukami, Ph.D., Forster Family Chair in Cancer Prevention at the Masonic Cancer Center and Professor of Psychiatry at the University of Minnesota. Dr. Hatsukami's areas of expertise include nicotine addiction and its treatment, including testing medications such as nicotine vaccine and combination medications, in smokers.

 

We are also announcing the call for poster abstracts focused on research related to tobacco regulatory science or tobacco control. Abstracts will be evaluated on the basis of scientific merit. Please send submissions (including title, authors, affiliations, and 250-word abstract) to Diann Gaalema at diann.gaalema@med.uvm.edu by August 15. 
For conference program, registration and hotel links, please visit our conference webpage.
Can't attend the conference? Watch it LIVE at: https://livestream.com/VCBH/Conference2019 

2019-07-11

[#DIV28SUPER] Submit Behavioral and Social Sciences Accomplishments by July 31, 2019 – Help the NIH Generate a Comprehensive List!

The NIH Office of Behavioral and Social Sciences Research (OBSSR) is seeking comment and input from the research and health/public health communities to help inform a list of impactful public health and healthcare accomplishments/contributions resulting from behavioral and social sciences research (BSSR). Follow this link to view how NIH defines BSSR. Note: This BSSR accomplishments list will be broad and will not be limited to NIH-funded research.

On Monday, April 22, OBSSR launched its IdeaScale website, a public comment platform, to engage the research community-at-large for the development of a broad accomplishments list. Your feedback will be used to make the list of accomplishments as meaningful as possible and to communicate the significance of BSSR.

OBSSR is using IdeaScale to make it easy to submit to this list of accomplishments. (Once an IdeaScale account is created, a user can submit comments, browse and respond to comments that have already been submitted, and vote for their favorites.) OBSSR wants your input!

 

Please forward this information to your colleagues or other contacts who may be able to provide feedback and inform this list of BSSR accomplishments.


The deadline to participate in this BSSR accomplishments crowdsource is Wednesday, July 31, 2019 at midnight ET.

For inquiries or more information, contact: OBSSRnews@mail.nih.gov.

 

 

Many thanks,

Erica Moore

Communications Director

Office of Behavioral and Social Sciences Research

National Institutes of Health

P: 301-594-4392

E: erica.moore2@nih.gov

 

Patricia Clem Kobor | Sr. Science Policy Analyst

Government Relations | (202) 336-5933| pkobor@apa.org

American Psychological Association: www.apaservices.org

Twitter: @APA, @APAScience

Advancing psychology to benefit society and improve people's lives

 

 

 

2019-07-10

[#DIV28SUPER] American Psychological Association Prize for Interdisciplinary Team Research

Dear all,


As you plan your APA convention attendance, please note the following session, which is based on the fact that the Center for Study of Tobacco Products at VCU won the American Psychological Association Prize for Interdisciplinary Team Research. Congratulations to Dr. Eissenberg and team!


"Interdisciplinary Science and Tobacco Product Regulation—Informing the FDA About Electronic Cigarettes", Sunday August 11, 10:00 am-11:50 am in room W187a, Level 1-West Building of the McCormick Place Convention Center.


Best,
Matt
--
Matthew W. Johnson, Ph.D.
Google Scholar: https://scholar.google.com/citations?user=fWhYUvwAAAAJ&hl=en
Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD  21224-6823
Tel: 410-550-0056
Fax: 410-550-0030
Email: mwj@jhu.edu

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Division 28 Program Highlights - APA 2019 Convention

Hello all, 


Please see attached for our exciting Division 28 program highlights for the 2019 APA convention in Chicago (August 8-11). Please feel free to distribute far and wide. 


And just a reminder that additional details on the full APA program can be found at the APA website (https://convention.apa.org/), as well as information on downloading the mobile app for easy viewing and schedule planning.  


We hope to see you all there! 


Meredith


_______________________________

Meredith S. Berry, Ph.D.
Assistant Professor
Department of Health Education and Behavior
Department of Psychology
University of Florida
2019 Program Chair -- Division 28 Psychopharmacology and Substance Abuse​
Gainesville, Florida 32611
Email: mberry@ufl.edu

2019-07-05

[#DIV28SUPER] Division 28 Survey Invitation

Dear Division 28 members. Please see the following survey invitation by Division members Bill Stoops and Justin Strickland.  Best, Matt

-------------------------------------------------------------------------------------------

Hello,


You are being invited to take part in a research study on feelings about clinical research participation. The entire study will take place using a web-based survey where you will be asked to answer questions about hypothetical research scenarios, attitudes, and behaviors. Note that you do not have to conduct clinical or human research yourself to participate and the survey is open to anyone willing to participate that is 18 years of age or older.


The survey will take approximately 10 minutes to complete. If you complete the survey, you will be entered to win one of fifty $20 Amazon gift cards. This gift card will be sent to you via an email entered in a survey separate from the survey containing your responses.

The survey is located in the link below as is a cover letter providing more details about the study. We hope that you will find the time to complete this brief survey.


https://uky.az1.qualtrics.com/jfe/form/SV_3n4VJMLbSvQPB1X


This project has been approved by the University of Kentucky Institutional Review Board (IRB). If you have questions about the study contact the Principal  Investigator William W. Stoops, Ph.D. at 859-257-5388 or at William.stoops@uky.edu or the Study Coordinator Justin C. Strickland, Ph.D. at Justrickland@uky.edu. Thank you in advance for your assistance with this important project.


Sincerely,

William W. Stoops, Ph.D. and Justin C. Strickland, Ph.D.

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2019-07-04

[#DIV28SUPER] Call for Papers: Experimental and Clinical Psychopharmacology

Special Issue for April 2020 on:

Advancing the Translation Between Clinical and Preclinical Models of Individual Differences in Vulnerability in Substance Use Disorders

This special issue will provide an overview of current translational research from both human and nonhuman animal researchers investigating individual difference factors in vulnerability to drug and alcohol use disorders. The goal of this special issue is to highlight translational clinical and preclinical research and to catalyze future translational approaches in the field. We encourage submission of review articles and original research reports in these areas, including individual difference factors in environmental, trait, and/or genetic domains. We encourage research that is translational in nature and would be especially interested in paired-research articles from different laboratories that are investigating the same individual difference factors across clinical and preclinical models. If submitting paired articles, authors are also invited to submit a comment on that set of articles. Nonhuman animal research that is translatable to the human conditions and human research that can be back translated to a nonhuman model are preferred. Papers addressing a variety of substances, including alcohol, marijuana, stimulants, and opiates, and their disorders, are welcome.

Researchers in this area may submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on Advancing the Translation Between Clinical and Preclinical Models of Individual Differences in Vulnerability to Substance Use Disorders.  All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2019 will be considered for inclusion in the special issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft of the title and abstract.

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Melissa A. Cyders, PhD, at mcyders@iu.edu or Dustin J. Stairs, PhD, at dustinstairs@creighton.edu, or the Editor, William W. Stoops, PhD at william.stoops@uky.edu.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

Interim Director
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2019-07-02

[#DIV28SUPER] In need of Science Student Council Nominations for APA

We are in need of Science Student Council Nominations for APA. I assume the student would need to be a student affiliate of APA. We definitely need students to represent science in APA.

The deadline for nominations (including self nominations) for the Science Student Council has passed, and we only received 1 for biopsychology, 2 for cognitive, and 2 for developmental. We received 0 nominations in I/O and methodology. Therefore, we are extending the deadline until July 30 and reaching out to you to help spread the word.

To apply, students would submit an essay on how they might contribute to SSC, a description of their research, a 2 page CV, and a brief letter of recommendation from their advisory.

If you know of any good candidates, would you please share this opportunity with them? More information can be found athttps://www.apa.org/science/leadership/students/nominations.


Thanks,
Suzette


Suzette M. Evans, Ph.D.
Professor of Clinical Neurobiology
Director of the Women's Research Center
Columbia University Medical Center and the New York State Psychiatric Institute
1051 Riverside Drive
Unit 66, Room 3704
New York NY 10032
se18@cumc.columbia.edu
Voice: 646-774-6136

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] Families in Psychology Project

Posted on behalf of Kaylie Gilston

Families in Psychology Project (https://www.familiesinpsych.org/) is launching a new mentoring program for graduate students and early career psychologists who are juggling academic and parenting responsibilities. We recognize the struggles of these two very important jobs and want to make sure you have the support you need to succeed in both! Mentors and mentees are welcome across all psychology fields and career levels. If you have any questions please feel free to reach out to us at familiesinpsych@gmail.comotherwise click on the link below to sign up:

https://www.surveygizmo.com/s3/5056748/FIPP-Mentorship-Program-Survey

We are hoping to match mentors/mentees before APA as we will be hosting a social hour (co-sponsored by APAGS, CECP, and Bridge Psychology Network) on Saturday at 4pm which can provide an opportunity to meet in person. For more information about that please check the APA program.

Families in Psychology Project Advocacy Team

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org